Vitamin B12 and folate deficiency: diagnosis and treatment

Vitamin B12 and folate deficiency are among the most clinically consequential nutritional deficiencies managed in Australian general practice — not because they are rare, but because the neurological complications of unrecognised or undertreated B12 deficiency can be irreversible. The macrocytic anaemia that both vitamins produce is often the presenting lab finding, but B12 deficiency additionally causes subacute combined degeneration of the spinal cord, peripheral neuropathy, optic neuropathy, and cognitive impairment — all potentially preventable if identified early and treated promptly.

Therapeutic Guidelines (eTG) and the Royal College of Pathologists of Australasia both recommend testing B12 and folate simultaneously at first presentation, since the two deficiencies can coexist and their management is interdependent. The governing principle is simple: treat B12 first if there is any uncertainty, because folate supplementation alone in unrecognised B12 deficiency can mask the haematological findings while allowing neurological damage to progress silently.

A. Core clinical — the AU general-practice framework

Physiology and body stores

Vitamin B12 (cobalamin) is present exclusively in animal-source foods. Daily requirements are small (2.4 µg/day in adults), but the absorption pathway is complex: gastric acid and pepsin release food-bound B12; it binds to intrinsic factor (IF) secreted by gastric parietal cells; the B12-IF complex is absorbed at the terminal ileum via cubilin receptors. Body stores (2–5 mg in the liver) sustain normal function for three to five years after absorption stops — so deficiency is often slow to develop and slow to declare itself clinically.

Folate is present in leafy green vegetables, legumes, and liver; Australian bread has been mandatorily fortified with folic acid since 2009 per Food Standards Australia New Zealand (FSANZ). Body stores are much smaller (5–10 mg), and deficiency emerges within weeks to a few months of inadequate intake.

Both vitamins are essential for nucleotide synthesis (explaining the macrocytic anaemia) and for single-carbon metabolism. B12 is additionally required for myelin maintenance — its deficiency disrupting fatty acid synthesis in the nervous system and producing the characteristic neurological syndrome.

Causes

B12 deficiency:

• Pernicious anaemia — autoimmune gastritis with anti-intrinsic-factor and anti-parietal-cell antibodies; the most common cause in older adults in Australia per RACGP AJGP
• Dietary: strict vegan or vegetarian diet; breastfed infants of B12-deficient mothers
• Post-surgical: gastrectomy, Roux-en-Y gastric bypass, sleeve gastrectomy (loss of parietal cells or bypass of stomach/proximal ileum)
• Ileal disease or resection: Crohn’s disease, radiation enteritis, ileal resection
• Medication-induced: long-term metformin (≥4–5 years) disrupts calcium-dependent ileal B12 absorption; long-term PPIs or H2-receptor antagonists reduce gastric acid needed to liberate food-bound B12; nitrous oxide (recreational nangs) inactivates B12 enzymatically
• Chronic atrophic gastritis: often asymptomatic; associated with H. pylori infection history

Folate deficiency:

• Dietary: alcohol use disorder (poor intake and increased liver metabolism); elderly on restricted diets; severe malnutrition
• Malabsorption: coeliac disease, tropical sprue, jejunal Crohn’s disease
• Increased demand: pregnancy, lactation, haemolytic anaemia, extensive psoriasis
• Drug-induced: methotrexate (dihydrofolate reductase antagonist — always co-prescribe folate 5 mg weekly); phenytoin and other anticonvulsants; sulfasalazine; trimethoprim; oral contraceptive (modest)
• Dialysis: folate is dialysable; haemodialysis patients need supplementation

Clinical features

Haematological (both B12 and folate): fatigue and reduced exercise tolerance; pallor; dyspnoea; palpitations; glossitis (smooth beefy-red tongue); angular cheilitis; mild jaundice from intramedullary haemolysis. Severe deficiency produces pancytopenia with risk of infection and bleeding.

Neurological (B12 only — this is the key differentiator):

• Subacute combined degeneration of the spinal cord: progressive symmetrical damage to posterior columns (vibration and proprioception loss, positive Romberg, sensory ataxia) and lateral corticospinal tracts (spasticity, hyperreflexia, extensor plantar responses)
• Peripheral neuropathy: symmetrical distal numbness and paraesthesiae, burning feet, gait instability
• Cognitive impairment: memory difficulties, slowed processing, executive dysfunction; rarely psychosis
• Critically: neurological B12 deficiency occurs in approximately 30% of cases without macrocytic anaemia — a normal MCV does not exclude B12 deficiency

History

Key questions: diet (vegan, vegetarian, restricted); alcohol; bariatric or gastric surgery history; GI conditions (Crohn’s disease, coeliac); medications (metformin, PPIs, methotrexate, phenytoin, sulfasalazine); nitrous oxide use; pregnancy or planning; prior B12 supplementation or injections.

Symptom enquiry: fatigue, glossitis, paraesthesiae, gait changes, cognitive change, mood, neuropathic features.

Examination

Pallor, glossitis, angular cheilitis; neurological examination — vibration sense at the great toe, proprioception, Romberg test, reflexes, plantar responses, gait.

Investigations

First-line per eTG and RCPA Manual:

• FBC + film 65070: macrocytic anaemia, oval macrocytes, hypersegmented neutrophils (≥5% with ≥5 lobes, or any with 6 lobes)
• Serum B12 66838: low <150 pmol/L; borderline 150–220 pmol/L — requires clinical correlation
• Serum folate 66602
• TSH, UEC, LFT: exclude hypothyroidism, renal, or liver-related macrocytosis

Cause workup for B12 deficiency:

• Anti-intrinsic-factor antibody: high specificity (>95%) for pernicious anaemia; sensitivity ~50–60%
• Anti-parietal-cell antibody: sensitive but less specific
• Coeliac serology (anti-tTG IgA + total IgA) for malabsorption pattern
• Gastroscopy where pernicious anaemia or atrophic gastritis is confirmed (gastric carcinoma risk)

B. Evidence appraisal — oral versus IM, and the folate-first trap

Oral high-dose B12 is non-inferior in most patients

The Cochrane systematic review (Vidal-Alaball 2018) — covering multiple RCTs including the ESCALOC trial — demonstrated that oral cyanocobalamin 1000–2000 µg daily produces equivalent biochemical restoration and clinical improvement to IM hydroxocobalamin in most causes of B12 deficiency, including pernicious anaemia. The mechanism: approximately 1% of oral B12 is absorbed by passive diffusion, independent of intrinsic factor — sufficient at these doses to meet requirements. AMH and eTG both acknowledge oral high-dose as a valid option.

The evidence-based Australian position: IM hydroxocobalamin is preferred for severe neurological disease (rapid, reliable correction), for patients with significant GI malabsorption where passive absorption may be inadequate, and for adherence-challenged patients. Oral high-dose is appropriate for dietary deficiency, pernicious anaemia without severe neurological involvement, and patients who prefer to avoid injections.

The danger of treating folate alone

Multiple BCSH guideline iterations and eTG reinforce: do not give folate in isolation when B12 has not been measured or when it is borderline-low. Folate treatment corrects the blood count but not the neurological damage — which progresses silently. This is not theoretical: case series and mechanistic data support the clinical dictum. Always measure both; treat B12 first or simultaneously.

Periconception folate

The Australian Pregnancy Care Guidelines and the MRC Vitamin Study (1991) established the periconception folate recommendation: 0.4 mg daily from at least one month before conception through 12 weeks gestation for standard-risk women; 5 mg daily for higher-risk groups. FSANZ mandatory fortification of wheat flour for bread-making (since 2009) provides approximately 50–100 µg folic acid per day from bread consumption — population-level NTD reduction — but does not replace individual supplementation.

C. Replacement regimens

B12 — IM hydroxocobalamin (Australian standard)

Without neurological involvement:

• Loading: 1 mg IM on alternate days for five to seven doses (approximately two weeks)
• Maintenance: 1 mg IM every three months indefinitely for irreversible causes (pernicious anaemia, ileal pathology, post-gastrectomy)

With neurological involvement:

• Loading: 1 mg IM on alternate days until maximum neurological improvement, then every three months

PBS pbs.gov.au: hydroxocobalamin 1 mg/mL injection is general schedule (no Authority); practice nurse administration MBS 10997 enables bulk-billable three-monthly injection clinics.

B12 — oral high-dose alternative

Cyanocobalamin 1000–2000 µg orally daily. OTC and widely available. Not PBS-listed (supplement category), but low cost. Sublingual formulations provide the same benefit via the same passive-diffusion mechanism. Review adherence and levels at 1–3 months.

Folate replacement

Folic acid 5 mg PO daily for four months — replenishes stores. Continue longer if the underlying cause is ongoing (chronic haemolysis, methotrexate co-prescription, coeliac disease with incomplete dietary response, dialysis).

Methotrexate co-prescription: folic acid 5 mg once weekly, taken 24–72 hours after the MTX dose (not on the same day — allows MTX to act before folate repletes the pathway).

Re-testing

FBC and reticulocyte count at 7–10 days after starting replacement — reticulocytosis at days 4–7 confirms a haematological response to megaloblastic anaemia. B12 and folate levels at one and four months to confirm restoration. Annual FBC and TFT in confirmed pernicious anaemia.

D. Australian operations

MBS items (verified MBS Online):

• Standard GP consultations: 23 / 36 / 44
• B12 assay: 66838
• Folate assay: 66602
• FBC: 65070
• Anti-parietal cell / anti-intrinsic factor antibody: 66518
• Coeliac serology (anti-tTG IgA): 66608
• Practice nurse (B12 IM injection): 10997
• GPMP/TCA: 721/723 for complex nutritional/haematological planning
• ATSI Health Assessment: 715 — annual assessment includes B12/folate where relevant

PBS pbs.gov.au: hydroxocobalamin 1 mg/mL injection is general schedule. Folic acid 5 mg tablets are general schedule (PBS). Cyanocobalamin oral and sublingual are OTC supplements.

Practical tips: set up a practice nurse-administered IM recall every three months for pernicious anaemia patients — this integrates well into a chronic disease management recall system. Pernicious anaemia patients have approximately two to three times the general population risk of gastric carcinoma: RACGP AJGP guidance recommends gastroscopy at diagnosis and consideration of repeat surveillance every three to five years.

E. Special populations

Pregnancy

The Australian Pregnancy Care Guidelines recommend periconception folic acid (0.4 mg standard; 5 mg high-risk) starting at least one month before conception and continuing to 12 weeks. B12 deficiency in pregnancy warrants IM replacement; hydroxocobalamin is safe. Screen the newborn for B12 deficiency if the mother has pernicious anaemia or is vegan — breastfed infants of B12-deficient mothers are at risk of neurological injury.

Vegan and strict vegetarian patients

B12 supplementation is non-negotiable for vegans — adequate B12 cannot be reliably obtained from plant foods (algae and fermented foods contain mostly inactive analogues). Recommend daily cyanocobalamin 50–100 µg, or 1000 µg twice weekly. Annual B12 level review.

Post-bariatric surgery patients

All patients after Roux-en-Y gastric bypass or sleeve gastrectomy require lifelong B12 supplementation — oral 1000 µg daily or IM three-monthly. Also supplementing iron, calcium with vitamin D, folate, and a daily multivitamin per bariatric protocol. Annual bloodwork review including B12, folate, iron studies, and vitamin D.

Long-term metformin users

Annual B12 level after five years of continuous metformin use per NHMRC Nutrient Reference Values guidance and eTG. If deficient, supplement — metformin can usually be continued alongside B12 replacement.

Nitrous oxide (recreational use)

Nitrous oxide inactivates B12 by oxidising its cobalt centre. Recreational use (“nangs”) in young adults is a rising cause of acute B12 neurological deficiency presentations. Management: IM B12 immediately, neurology referral for subacute combined degeneration pattern, harm-reduction counselling.

When to escalate

Refer or escalate when:

• Neurological signs (subacute combined degeneration, peripheral neuropathy) — haematology and neurology; intensive IM loading
• Severe pancytopenia — haematology
• Confirmed pernicious anaemia with alarm features (weight loss, dysphagia, melaena) — gastroenterology for gastroscopy and exclusion of gastric carcinoma
• Pregnancy with unexplained macrocytic anaemia — obstetric and haematology input
• B12 deficiency with suspected underlying malabsorption not responding to treatment — gastroenterology

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — Therapeutic Guidelines (eTG), AMH, Australian Pregnancy Care Guidelines, RCPA Manual, and RACGP. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about specific investigation and treatment are made with your own GP and treating clinicians.

Consumer resources: HealthDirect — Vitamin B12 deficiency, Better Health Channel — Vitamin B12.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Endocrinology: vitamin deficiencies
2. RACGP — Pernicious anaemia and autoimmune gastritis (AJGP)
3. Australian Pregnancy Care Guidelines — folate and B12 in pregnancy
4. NHMRC Nutrient Reference Values — B12 and folate
5. RCPA Manual — vitamin B12 and folate testing
6. FSANZ — mandatory folic acid fortification of bread
7. Australian Medicines Handbook (AMH)
8. PBS — hydroxocobalamin and folic acid
9. Vidal-Alaball J et al — Oral vs IM B12 (Cochrane 2018)
10. MBS Online — item search
11. HealthDirect — Vitamin B12 deficiency
12. Better Health Channel — Vitamin B12